(Q63241939)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Factors affecting drug concentrations and QT interval during thioridazine therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

R H K Thanacoody

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

J G Reilly

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

I N Ferrier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

S H L Thomas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

25 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

555-565

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Antipsychotics and the risk of sudden cardiac death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Thioridazine and sudden unexplained death in psychiatric in-patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

The heart of psychotropic drug therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Thioridazine-5-sulfoxide cardiotoxicity in the isolated, perfused rat heart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Thioridazine and EKG anomalies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100195

1 reference

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17460606%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference